Kailera Therapeutics (KLRA) Net Income — Quarterly & Annual

Screener

Net Income at other companies

Exxon MobilXOM

$4.18B-45.8%

VeradermicsMANE

-$27.23M-120%

GPA

General Purpose Acquisition Corp.GPAC

-$5.23M-37.4%

GPA

General Purpose Acquisition Corp.GPAC

-$5.23M-37.4%

Polaryx Therapeutics, Inc.PLYX

-$2.54M+49.6%

Polaryx Therapeutics, Inc.PLYX

-$2.54M+49.6%

Other financials

Income statement

Operating income-$84.7M-314%

Net income-$78.9M-339%

EPS (diluted)-$3,650.00+79.7%

Balance sheet

Cash & equivalents$111.8M+9.9%

Total debt$10.5M—

Total equity-$432.1M-83.7%

Total assets$624.8M—

Cash flow

Operating cash flow-$68.3M-275%

Valuation

Market cap$2.44B-15.8%

Enterprise value$2.34B—

Returns & leverage

Debt / equity-0×—

Current ratio9.7×—

Where this comes from

Reported directly by Kailera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Kailera Therapeutics’s 10-Q, filed May 26, 2026. Open the filing →

Filed: May 26, 2026, 4:29 PM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0001193125-26-239417

FAQ

What is Kailera Therapeutics's net income?: Kailera Therapeutics (KLRA) reported net income of -$78.87M in Q1 2026.
What does net income mean?: Net income as the starting point for the indirect method operating cash flow reconciliation.

Ask your AI about Kailera Therapeutics's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk